MX2020004455A - Derivados de pirrolopirazina como inhibidores de integrina alfa v. - Google Patents

Derivados de pirrolopirazina como inhibidores de integrina alfa v.

Info

Publication number
MX2020004455A
MX2020004455A MX2020004455A MX2020004455A MX2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A MX 2020004455 A MX2020004455 A MX 2020004455A
Authority
MX
Mexico
Prior art keywords
alpha
integrin inhibitors
pyrrolopyrazine derivatives
pyrrolopyrazine
derivatives
Prior art date
Application number
MX2020004455A
Other languages
English (en)
Spanish (es)
Inventor
Guohua Zhao
James Mignone
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020004455A publication Critical patent/MX2020004455A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2020004455A 2017-11-07 2018-11-05 Derivados de pirrolopirazina como inhibidores de integrina alfa v. MX2020004455A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582693P 2017-11-07 2017-11-07
PCT/US2018/059157 WO2019094319A1 (en) 2017-11-07 2018-11-05 Pyrrolopyrazine derivatives as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
MX2020004455A true MX2020004455A (es) 2020-07-24

Family

ID=64362756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004455A MX2020004455A (es) 2017-11-07 2018-11-05 Derivados de pirrolopirazina como inhibidores de integrina alfa v.

Country Status (14)

Country Link
US (1) US11292802B2 (https=)
EP (1) EP3707142B1 (https=)
JP (1) JP7291696B2 (https=)
KR (1) KR102700471B1 (https=)
CN (1) CN111433207B (https=)
AU (1) AU2018365793A1 (https=)
BR (1) BR112020008893A2 (https=)
CA (1) CA3081805A1 (https=)
EA (1) EA202091136A1 (https=)
ES (1) ES2904645T3 (https=)
IL (1) IL274425A (https=)
MX (1) MX2020004455A (https=)
SG (1) SG11202004077WA (https=)
WO (1) WO2019094319A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102700471B1 (ko) * 2017-11-07 2024-08-28 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 피롤로피라진 유도체
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
CA2309204A1 (en) 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists
CA2315370A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
JP2004521079A (ja) 2000-08-29 2004-07-15 ファルマシア・コーポレーション アルファーvベータ3アンタゴニストとして有用な二環式環系を含有する化合物
CA2436130A1 (en) * 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
EP1592421A1 (en) 2002-12-20 2005-11-09 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US7365209B2 (en) 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のa5b1アンタゴニストとしてのN−(ベンゾイル)−O−[2−(ピリジン−2−イルアミノ)エチル]−L−チロシン誘導体と関連化合物
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
JP2011184298A (ja) 2008-06-02 2011-09-22 Sanwa Kagaku Kenkyusho Co Ltd 新規化合物及びその医薬用途
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
KR102700471B1 (ko) * 2017-11-07 2024-08-28 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 피롤로피라진 유도체

Also Published As

Publication number Publication date
SG11202004077WA (en) 2020-05-28
CA3081805A1 (en) 2019-05-16
AU2018365793A1 (en) 2020-06-18
ES2904645T3 (es) 2022-04-05
WO2019094319A1 (en) 2019-05-16
CN111433207B (zh) 2023-07-25
EA202091136A1 (ru) 2020-07-29
BR112020008893A2 (pt) 2020-10-13
US20210163501A1 (en) 2021-06-03
JP7291696B2 (ja) 2023-06-15
EP3707142A1 (en) 2020-09-16
EP3707142B1 (en) 2021-12-08
CN111433207A (zh) 2020-07-17
IL274425A (en) 2020-06-30
KR102700471B1 (ko) 2024-08-28
US11292802B2 (en) 2022-04-05
JP2021502358A (ja) 2021-01-28
KR20200084879A (ko) 2020-07-13

Similar Documents

Publication Publication Date Title
MX2020003430A (es) Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana.
MX2020004287A (es) Procesamiento de biomasa.
MX2020004455A (es) Derivados de pirrolopirazina como inhibidores de integrina alfa v.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
IL277455A (en) History of aminopyrimidines as CTPS1 inhibitors
MX2020003760A (es) Formulaciones de niraparib.
MX2020004708A (es) Sistema y metodos de transporte.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2020004424A (es) Formulacion aerosolizable.
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020003439A (es) Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
MY165760A (en) Absorbent article
CA192893S (en) Bottle
MX2020003440A (es) Red de seguridad.
MX2020004662A (es) Ajuste planificado del contorno mediante especificaciones correspondientes.
MX2019015167A (es) Farmacos antivirales.
MX2020003616A (es) Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene.
MX2020004008A (es) Caja de carton y plantilla para la misma.
MX2020002908A (es) Composicion acuosa de polimeros.
MX2020003611A (es) Metodos de refuerzo del pozo.
MX2020003487A (es) Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos.
MX2020003703A (es) Composiciones de sabor.
MX2020004282A (es) Embalaje del producto.
MX2020003498A (es) Agentes de raleo de frutos que contienen diuron.